combination therapy with glp-1 receptor agonist and sglt2 inhibitor Schematic illustration of monoagonists, dual agonists triple SGLT2 Inhibitors vs. GLP-1 Agonists

Characterisation of glucose-dependent insulinotropic polypeptide receptor antagonists in rodent pancreatic beta cells and mice

Organizations lacking poly-agonist programs face an increasingly difficult competitive position

Metabolism GLP-1 gets rapidly metabolized in the circulation by dipeptidyl peptidase-4 (DPP-IV), resulting in a short plasma half-life of approximately 2 min [11]

The most common include nausea, vomiting, gastrointestinal discomfort, and, less frequently, headaches or fatigue

Preferred therapy: Insulin remains the gold standard

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study